STATE OF CLEVELAND * 1 0 4 2 7 0 7 5 1 7 *

FILED In The

Office of the Court Clerk

IN THE DISTRICT COURT OF CLEVELAND COUNTY STATE OF OKLAHOMA

JAN 17 2019

STATE OF OKLAHOMA, ex rel., MIKE HUNTER, ATTORNEY GENERAL OF OKLAHOMA,) In the office of the) Court Clerk MARILYN WILLIAMS)
Plaintiff,) Case No. CJ-2017-816
vs.) <u>CONFIDENTIAL</u>) FILED UNDER SEAL
PURDUE PHARMA L.P., et al,) PURSUANT TO
Defendants.) PROTECTIVE ORDER) DATED APRIL 16, 2018

SUPPLEMENT TO DEFENDANTS' EMERGENCY MOTION TO COMPEL AND FOR EXTENSION OF TIME FOR DEFENDANTS' EXPERT DISCLOSURES

Defendants respectfully submit this Supplement to their Emergency Motion to Compel and for Extension of Time, filed on January 7, 2019, in order to notify the Court of relevant information just learned by Defendants. Specifically, Defendants have just come to learn that since as early as May 2018, the State has been collecting hundreds of thousands of pages of patient medical records, which are well within the parameters of the general fact discovery served by Defendants and on which the State's experts rely. But the State did not begin to share these records until December 28, 2018. At that time, the state dumped 325,000 pages on Defendants, in undifferentiated form, without any way for Defendants to timely review – let alone analyze – the vast trove of relevant information on which the State is staking its claims.

It is clear from the State's expert disclosures that Dr. Jason Beaman is one of the State's key experts. Dr. Beaman purports to review a sample of SoonerCare opioid patient medical records in order to determine which prescriptions are "medically unnecessary":

Dr. Beaman is expected to testify that he reviewed a total of 1,612 individual records composing of 38,498 unique opioid prescriptions. Dr. Beaman is further expected to testify that upon review of these medical records and applying the methodology described below, Dr. Beaman concluded that 8,059 opioid prescriptions out of the 1,612 individual records composing of 38,498 unique prescriptions reviewed were medically unnecessary.

Other of the State's experts, in turn, use and rely on Dr. Beaman's analysis to compute the State's request for damages, rendering Dr. Beaman's analysis a core component of the State's case.

In order to test the validity of Dr. Beaman's analysis and opinions and to prepare their own expert discloures, Defendants need and are entitled to a meaningful opportunity to review and analyze, among other things, the underlying medical records that Dr. Beaman relied on. But through its refusal and failure to timely produce these materials (including the State's medical claims database that houses medical information directly related to the prescriptions Dr. Beaman

now puts at issue) and other documents as part of basic fact discovery, the State has effectively deprived Defendants of that opportunity, raising serious due process concerns.

The State's opposition seeks to misdirect the Court's attention to avoid the salient point. There are many pages of records that should have been produced months ago, as part of basic fact discovery. While the State and its experts have been analyzing these underlying factual materials for many months, the State wants Defendants and their experts to do it in just a matter of a few weeks. Defendants are being sandbagged by design.

We now know that the State issued litigation requests for and began receiving copies of the underlying factual records, which total over 325,000 pages, for purposes of this litigation, as early as *May 2018*. For example,

There can be no serious question that such documents are discoverable. The State should have – but failed to – produce these documents and others to Defendants on a rolling basis as part of general fact discovery.

Instead, the State decided to wait until December 28, 2018, to begin dumping an undifferentiated mass of raw documents on Defendants, including documents produced as "OKAGSS_001-OKAGSS_005." These belated productions consist of more than 325,000 pages containing decades of patient medical information, much of which is handwritten and thus difficult to read, let alone synthesize into any usable format. While Defendants are reviewing these documents, their various experts need to time to analyze these dilatory productions (in a

usable format) – and the additional expert-related documents that the State continues to produce.¹

Finally, the State has failed to produce any worksheet, other document, or other information that identifies *which* opioid prescriptions were (according to Dr. Beaman) medically unnecessary. All Defendants have been told is that he believes "8,059 opioid prescriptions" out of "38,498 unique prescriptions" were "medically unnecessary." But they have not been told *which* "8,059 opioid prescriptions" the State is putting at issue. Without having those 8,059 prescriptions identified as part of the State's expert interrogatory responses, there is no way to audit Dr. Beaman's work. Zero. The State is hiding the ball on a core issue in this case. That is neither fair nor the way the discovery system is designed to work.

Throughout general fact discovery, the State skirted its discovery obligations on the grand promise that its expert disclosures would cure its deficiencies. But we now know that promise rings hollow. Not only do the State's expert disclosures and recent productions uncover greater deficiencies, but they also raise more questions than they answer. The result is that Defendants have been deprived of their due process right to a meaningful opportunity to mount a defense.

Accordingly, among other things, Defendants respectfully request the Court to compel the State to produce Dr. Beaman's worksheets or other documents that specify *which* "8,059 opioid prescriptions" out of "38,498 unique prescriptions" were (according to him) "medically unnecessary." Defendants cannot be expected to "Go Fish." Defendants further request that the medical records (OKAGSS_001-OKAGSS_005) be produced in the same format in which Dr. Beaman and the State's other experts had access. For example, if the medical records were loaded into a sortable and searchable database, the State should be required to produce the

¹ The State has continued to produce expert-related documents as recently as January 11, 2019.

records in that format to Defendants so that Defendants have the same functionality. Defendants also reiterate their request that Defendants' expert disclosure deadline be extended for at least 60 days from the Court's certification that the State's production is complete so that Defendants and their experts can properly analyze the hundreds of thousands of underlying factual records that the State has withheld from production for many months.

Date: January 16, 2019

Respectfully submitted,

Sanford C. Coats, OBA No. 18268 Joshua D. Burns, OBA No. 32967

CROWE & DUNLEVY, P.C.

Braniff Building

324 N. Robinson Ave., Ste. 100

Oklahoma City, OK 73102

Tel: (405) 235-7700 Fax: (405) 272-5269

sandy.coats@crowedunlevy.com joshua.burns@crowedunlevy.com

Of Counsel:

Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul A. LaFata DECHERT, LLP Three Bryant Park

1095 Avenue of the Americas

New York, New York 10036

Tel: (212) 698-3500

Fax: (212) 698-3599

sheila.birnbaum@dechert.com mark.cheffo@dechert.com hayden.coleman@dechert.com

paul.lafata@dechert.com

Eric Wolf Pinker John Thomas Cox III

Lynn Pinker Cox & Hurst, LLP 2100 Ross Avenue, Suite 2700 Dallas, TX 75201 epinker@lynnllp.com tcox@lynnllp.com

Counsel for Purdue Pharma L.P.,
Purdue Pharma Inc., and The Purdue
Frederick Company Inc.

Benjamin H. Odom, OBA No. 10917 John H. Sparks, OBA No. 15661 ODOM, SPARKS & JONES PLLC HiPoint Office Building 2500 McGee Drive Ste. 140 Norman, OK 73072 Telephone: (405) 701-1863 Facsimile: (405) 310-5394

Email: odomb@odomsparks.com Email: sparksj@odomsparks.com

Larry D. Ottaway, OBA No. 6816 Amy Sherry Fischer, OBA No. 16651 FOLIART, HUFF, OTTAWAY & BOTTOM 201 Robert S. Kerr Avenue, 12th Floor Oklahoma City, OK 73102 larryottaway@oklahomacounsel.com amyfischer@oklahomacounsel.com

Charles C. Lifland O'MELVENY & MYERS LLP 400 S. Hope Street Los Angeles, CA 90071 Telephone: (213) 430-6000 Facsimile: (213) 430-6407 Email: clifland@omm.com

Stephen D. Brody
David K. Roberts
O'MELVENY & MYER\$ LLP
1625 Eye Street NW
Washington, DC 20006
Telephone: (202) 383-5300
Facsimile: (202) 383-5414

Email: sbrody@omm.com Email: droberts2@omm.com

Counsel for Defendants Janssen
Pharmaceuticals, Inc., Johnson & Johnson,
Janssen Pharmaceutica, Inc. n/k/a Janssen
Pharmaceuticals, Inc., and Ortho-McNeilJanssen Pharmaceuticals, Inc. n/k/a/
Janssen Pharmaceuticals, Inc.

Robert G. McCampbell, OBA No. 10390
Nicholas ("Nick") V. Merkley, OBA No. 20284
Ashley E. Quinn, OBA No. 33251
GABLEGOTWALS
One Leadership Square, 15th Fl. 211 North Robinson
Oklahoma City, OK 73102-7255
T: +1.405.235.3314

E-mail: RMcCampbell@Gablelaw.com E-mail: NMerkley@Gablelaw.com E-mail: AQuinn@Gablelaw.com

OF COUNSEL:

Steven A. Reed Harvey Bartle IV Mark A. Fiore MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103-2921 T: +1.215.963.5000

E-mail: steven.reed@morganlewis.com E-mail: harvey.bartle@morganlewis.com E-mail: mark.fiore@morganlewis.com

Brian M. Ercole
MORGAN, LEWIS & BOCKIUS LLP
200 S. Biscayne Blvd., Suite 5300
Miami, FL 33131
T: +1.305.415.3416
E-mail: hrian areala@marganlaysis.aar

E-mail: brian.ercole@morganlewis.com

Attorneys for Defendants Cephalon, Inc., Teva Pharmaceuticals USA, Inc., Watson Laboratories Inc., Actavis LLC, and Actavis

Pharma, Inc. f/k/a, Watson Pharma, Inc.

CERTIFICATE OF SERVICE

I hereby certify that on this 16th day of January 2019, I caused a true and correct copy of the following:

SUPPLEMENT TO DEFENDANTS' EMERGENCY MOTION TO COMPEL AND FOR EXTENSION OF TIME FOR DEFENDANTS' EXPERT DISCLOSURES

to be served via email upon the counsel of record listed on the attached Service List.

SERVICE LIST

WHITTEN BURRAGE

Michael Burrage
Reggie Whitten
512 N. Broadway Avenue, Suite 300
Oklahoma City, OK 73102
mburrage@whittenburragelaw.com
rwhitten@whittenburragelaw.com
Counsel for Plaintiff the State of Oklahoma

OKLAHOMA OFFICE OF THE ATTORNEY

GENERAL Mike Hunter Abby Dillsaver Ethan A. Shaner 313 NE 21st St

Oklahoma City, OK 73105 abby.dillsaver@oag.ok.gov ethan.shaner@oag.ok.gov

Counsel for Plaintiff the State of Oklahoma

NIX, PATTERSON & ROACH, LLP

Bradley E. Beckworth Jeffrey J. Angelovich

Lloyd "Trey" Nolan Duck, III

Andrew Pate Lisa Baldwin Nathan B. Hall

512 N. Broadway Ave., Suite 200

Oklahoma City, OK 73102 bbeckworth@nixlaw.com jangelovich@npraustin.com

tduck@nixlaw.com dpate@nixlaw.com lbaldwin@nixlaw.com nhall@nixlaw.com

Counsel for Plaintiff the State of Oklahoma

GLENN COFFEE & ASSOCIATES, PLLC

Glenn Coffee

915 N. Robinson Ave.

Oklahoma City, OK 73102

gcoffee@glenncoffee.com

Counsel for Plaintiff the State of Oklahoma

ODOM, SPARKS & JONES PLLC

Benjamin H. Odom
John H. Sparks
Michael W. Ridgeway
David L. Kinney
HiPoint Office Building
2500 McGee Drive Ste. 140
Oklahoma City, OK 73072
odomb@odomsparks.com
sparksj@odomsparks.com

ridgewaym@odomsparks.com

kinneyd@odomsparks.com

Counsel for Defendants Janssen

Pharmaceuticals, Inc., Johnson & Johnson, Janssen Pharmaceutica, Inc. n/k/a/ Janssen Pharmaceuticals, Inc., and Ortho-McNeilFOLIART, HUFF, OTTAWAY & BOTTOM

Larry D. Ottaway Amy Sherry Fischer

201 Robert S. Kerr Avenue, 12th Floor

Oklahoma City, OK 73102

larryottaway@oklahomacounsel.com

amy fischer@oklahomacounsel.com

Attorneys for Defendants Johnson & Johnson,

Janssen Pharmaceuticals, Inc., Janssen

Pharmaceutica, Inc. n/k/a Janssen

Pharmaceuticals, Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen

Pharmaceuticals, Inc.

Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc and Ortho-McNeil-Janssen Pharmaceuticals, Inc. n/k/a/ Janssen Pharmaceuticals, Inc.

O'MELVENY & MYERS LLP

Stephen D. Brody
David K. Roberts
1625 Eye Street NW
Washington, DC 20006
sbrody@omm.com
droberts2@omm.com
Counsel for Defendants Janssen
Pharmaceuticals, Inc., Johnson & Johnson,
Janssen Pharmaceutica, Inc. n/k/a/ Janssen
Pharmaceuticals, Inc., and Ortho-McNeilJanssen Pharmaceuticals, Inc and Ortho-McNeilJanssen Pharmaceuticals, Inc and Ortho-McNeilJanssen Pharmaceuticals, Inc and Ortho-McNeilJanssen Pharmaceuticals, Inc. n/k/a/ Janssen
Pharmaceuticals, Inc. n/k/a/ Janssen

DECHERT, LLP Sheila Birnbaum Mark S. Cheffo Hayden A. Coleman Paul A. LaFata Jonathan S. Tam Erik Snapp Three Bryant Park 1095 Avenue of the Americas New York, New York 10036 sheila.birnbaum@dechert.com mark.cheffo@dechert.com hayden.coleman@dechert.com paul.lafata@dechert.com jonathan.tam@dechert.com erik.snapp@dechert.com Counsel for Purdue Pharma L.P., Purdue Pharma Inc. and The Purdue Frederick Company Inc.

O'MELVENY & MYERS LLP
Charles C. Lifland
Jennifer D. Cardelús
400 S. Hope Street
Los Angeles, CA 90071
clifland@omm.com
jcardelus@omm.com
Counsel for Defendants Janssen
Pharmaceuticals, Inc., Johnson & Johnson,
Janssen Pharmaceutica, Inc., n/k/a/ Janssen
Pharmaceuticals, Inc., and Ortho-McNeilJanssen Pharmaceuticals, Inc., n/k/a/ Janssen
Pharmaceuticals, Inc.

LYNN PINKER COX & HURST, LLP Eric Wolf Pinker
John Thomas Cox III
Lynn Pinker Cox & Hurst, LLP
2100 Ross Avenue, Suite 27/00
Dallas, TX 75201
epinker@lynnllp.com
tcox@lynnllp.com
Counsel for Purdue Pharma L.P.,
Purdue Pharma Inc. and The Purdue
Frederick Company Inc.

GABLEGOTWALS
Robert G. McCampbell
Nicholas V. Merkley
Ashley E. Quinn
One Leadership Square, 15th Fl.
211 North Robinson
Oklahoma City, OK 73102-7255
RMcCampbell@Gablelaw.com
NMerkley@Gablelaw.com
AQuinn@Gablelaw.com
Attorneys for Defendants Cephalon, Inc., Teva
Pharmaceuticals USA, Inc., Watson
Laboratories, Inc., Actavis LLC, and Actavis
Pharma, Inc. f/k/a/ Watson Pharma, Inc.

MORGAN, LEWIS & BOCKIUS LLP
Brian M. Ercole
200 S. Biscayne Blvd., Suite 5300
Miami, FL 33131
brian.ercole@morganlewis.com
Attorneys for Defendants Cephalon, Inc., Teva
Pharmaceuticals USA, Inc., Watson
Laboratories, Inc., Actavis LLC, and Actavis
Pharma, Inc. f/k/a/ Watson Pharma, Inc.

MORGAN, LEWIS & BOCKIUS LLP
Steven A. Reed
Harvey Bartle IV
Rebecca Hillyer
Lindsey T. Mills
1701 Market Street
Philadelphia, PA 19103-2921
steven.reed@morganlewis.com
harvey.bartle@morganlewis.com
rebeccahillyer@morganlewis.com
lindsey.mills@morganlewis.com
Attorneys for Defendants Cephalon, Inc., Teva
Pharmaceuticals USA, Inc., Watson
Laboratories, Inc., Actavis LLC, and Actavis
Pharma, Inc. f/k/a/ Watson Pharma, Inc.

EXHIBIT A

FILED UNDER SEAL PER COURT ORDER DATED APRIL 16, 2018, THAD BALKMAN DISTRICT JUDGE